These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 14533729)

  • 61. Threat or opportunity? Secondary exchange in a setting with widespread availability of needles.
    Lenton S; Bevan J; Lamond T
    Subst Use Misuse; 2006; 41(6-7):845-64. PubMed ID: 16809175
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HIV vaccines for injection drug users in the context of a comprehensive prevention agenda.
    Vlahov D
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S3-6. PubMed ID: 7865324
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Analysis of a Targeted Intervention Programme on the Risk Behaviours of Injecting Drug Users in India: Evidence From the National Integrated Biological and Behavioural Surveillance Survey.
    Sahu D; Ranjan V; Chandra N; Nair S; Kumar A; Arumugam E; Rao MVV
    J Prev Med Public Health; 2022 Jul; 55(4):407-413. PubMed ID: 35940196
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Needle and syringe cleaning practices among injection drug users.
    Fisher DG; Harbke CR; Canty JR; Reynolds GL
    J Drug Educ; 2002; 32(2):167-78. PubMed ID: 12206065
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Commentary on Palmateer et al. (2010): next steps in the global research agenda on syringe access for injection drug users.
    Bluthenthal R; Kral A
    Addiction; 2010 May; 105(5):860-1. PubMed ID: 20402974
    [No Abstract]   [Full Text] [Related]  

  • 66. An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users.
    Richter A; Brandeau ML; Owens DK
    Med Decis Making; 1999; 19(2):167-79. PubMed ID: 10231079
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HIV-1 prevention: interdisciplinary studies on the efficacy of bleach and development of prevention protocols.
    McCoy CB; Shapshak P; Metsch LR; Rivers JE; McCoy HV; Weatherby NL; Shah SM; Chitwood DD
    Arch Immunol Ther Exp (Warsz); 1995; 43(1):1-9. PubMed ID: 8744677
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Should pharmacists have a role in harm reduction services for IDUs? A qualitative study in Tallinn, Estonia.
    Vorobjov S; Uusküla A; Abel-Ollo K; Talu A; Jarlais DD
    J Urban Health; 2009 Nov; 86(6):918-28. PubMed ID: 19921542
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Community coverage and HIV prevention: assessing metrics for estimating HIV incidence through syringe exchange.
    Heimer R
    Int J Drug Policy; 2008 Apr; 19 Suppl 1(Suppl 1):S65-73. PubMed ID: 18207726
    [TBL] [Abstract][Full Text] [Related]  

  • 70. HIV infection among intravenous drug users: epidemiology and risk reduction.
    Des Jarlais DC; Friedman SR
    AIDS; 1987 Jul; 1(2):67-76. PubMed ID: 3130084
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Harm reduction actions as a health care construction process at a public health center in Rosario, Argentina.
    Lavarello D; Lottero M; Chavero M; Toledo A; Espínola M; Gerlero S; Liborio M
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S353-7. PubMed ID: 14648446
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Are major reductions in new HIV infections possible with people who inject drugs? The case for low dead-space syringes in highly affected countries.
    Zule WA; Cross HE; Stover J; Pretorius C
    Int J Drug Policy; 2013 Jan; 24(1):1-7. PubMed ID: 22884539
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Can HIV-1-contaminated syringes be disinfected? Implications for transmission among injection drug users.
    Abdala N; Gleghorn AA; Carney JM; Heimer R
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):487-94. PubMed ID: 11744839
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of Amsterdam needle and syringe exchange.
    Buning EC
    Int J Addict; 1991 Dec; 26(12):1303-11. PubMed ID: 1787023
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The needle-borne HIV epidemic: causes and public health responses.
    Gostin L
    Behav Sci Law; 1991; 9(3):287-304. PubMed ID: 10148824
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Community pharmacist perspectives on HIV/AIDS and interventions for injection drug users in Canada.
    Myers T; Cockerill R; Worthington C; Millson M; Rankin J
    AIDS Care; 1998 Dec; 10(6):689-700. PubMed ID: 9924524
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HIV prevalence among intravenous drug users: model-based estimates from New Haven's legal needle exchange.
    Kaplan EH; Heimer R
    J Acquir Immune Defic Syndr (1988); 1992; 5(2):163-9. PubMed ID: 1732509
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Expanding access to syringes.
    Rose V
    Focus; 2007 Mar; 22(3):1-5. PubMed ID: 17549832
    [No Abstract]   [Full Text] [Related]  

  • 79. Injection drug users' perspectives on placing HIV prevention and other clinical services in pharmacy settings.
    Lutnick A; Case P; Kral AH
    J Urban Health; 2012 Apr; 89(2):354-64. PubMed ID: 22231488
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Syringe exchange for prevention of HIV infection in Sweden: practical experiences and community reactions.
    Christensson B; Ljungberg B
    Int J Addict; 1991 Dec; 26(12):1293-302. PubMed ID: 1787022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.